[2021] Non-Invasive Prenatal Testing (PNID) Market Growth With Healthy 10.3% CAGR To Reach US $ 1,936.4 Million Through 2028 | Ariosa Diagnostics, Inc., BGI Diagnosis Co., Ltd., Berry Genomics Corporation, Illumina, Inc.

The non-invasive prenatal test (DPNI) is a new method of detecting fetal chromosomal aneuploidy during pregnancy by evaluating fetal cell-free DNA circulating in the mother’s blood. This includes screening a baby or embryo for specific diseases or birth defects before the child is born.

Statistics:

The Global non-invasive prenatal testing market is expected to reach $ 1,936.4 million by 2027.

Global Non-Invasive Prenatal Testing Market: Drivers

The increasing incidence of chromosomal diseases is expected to propel the growth of the global non-invasive prenatal testing market during the forecast period. For example, according to a study published in the Journal of Korean Medical Science in August 2019 titled “Estimating Nationwide Prevalence of Live Births with Down Syndrome and Their Medical Expenditures in Korea”, the incidence of live births with Down syndrome was estimated to 5.03 per 10,000 births between 2007 and 2016.

In addition, an increased awareness of the benefits of non-invasive testing methods is expected to accelerate the growth of the global non-invasive prenatal testing market. During the first trimester of pregnancy, obstetricians gradually offer non-invasive diagnostics as a replacement for invasive procedures and the first diagnostic screening.

For more information, request a sample report at – https://www.coherentmarketinsights.com/insight/request-sample/579

Statistics:

In 2019, North America accounted for the largest share of the global non-invasive prenatal testing market, accounting for 45% of market revenue, followed by Europe and Asia-Pacific respectively.

Global Non-Invasive Prenatal Testing Market: Restraints

Irregular reimbursement rules and insurance coverage are expected to hamper the growth of the global non-invasive prenatal testing market during the forecast period. Updates to the current American Medical Association procedural terminology, or CPT codes, for non-invasive procedures and other molecular diagnostic tests have caused uncertainties about reimbursement and insurance coverage. Due to the increased expense of these tests, many vendors have limited success due to the limited or no coverage of these tests.

Further, the tests are copyrighted by a small number of vendors which are expected to hamper the growth of the global non-invasive prenatal testing market during the forecast period. Patents and exclusive licenses for technology used in non-invasive prenatal diagnosis are controlled by a few suppliers. As a result, there is no rivalry in the market and little incentive to reduce testing and quality assurance costs.

Global Non-invasive Prenatal Testing Market: Opportunities

Obtaining reimbursement by payers for testing is expected to offer attractive growth prospects for players in the global non-invasive prenatal testing market. Due to the high cost of these tests, providers may prioritize insurance coverage for the NIPT tests they provide.

Further, the focus on genetic counseling, health education, and NIPT grants are expected to drive the growth of the global non-invasive prenatal testing market during the forecast period. For example, researchers at Fudan University in China and University College London in the UK reported in September 2020 that in China, a higher percentage of women in Shenzhen noticed NIPT (87,30 % against 64.03%), were ready to accept the NIPT (91.80% vs 80.43%) and had benefited from a NIPT (83.12% vs 54.54%), while their level of satisfaction was relatively small.

To download the research PDF brochure here @ https://www.coherentmarketinsights.com/insight/request-pdf/579

Statistics:

The global non-invasive prenatal testing market was worth US $ 882.9 million in 2019 and is expected to reach US $ 1,936.4 million by 2027 more and more 10.3% CAGR during the forecast period 2020 – 2027.

Market trends / Key takeaways

The implementation of new guidelines is expected to boost the growth of the global non-invasive prenatal testing market during the forecast period. For example, the American College of Obstetricians and Gynecologists released new guidelines for non-invasive prenatal testing in August 2020.

The major players in the global non-invasive prenatal testing market are focusing their efforts on fundraising to increase their market share. For example, BillionToOne, Inc. raised US $ 15 million in March 2020 to help with the business expansion of UNITY, a prenatal screening test that directly assesses a baby’s risk of developing common and serious inherited disorders such as hemoglobinopathies, cystic fibrosis and spinal muscular atrophy, for all states of the United States and the research and development of potential diagnostic tests such as liquid biopsy products.

Regulations

Europe

  • A national screening program for congenital anomalies or aneuploidies is strictly avoided in Europe, as doctors and the national health service are NOT interested in interrupting as many people with disabilities as possible
  • But pregnant women are informed in good time by obstetricians of the existence of all available prenatal tests, mentioning the benefits, the associated risks and any difficult decisions arising from these tests.
  • All these non-invasive / risk calculation and invasive / diagnostic tests are offered at the request of pregnant women and are not mandatory. As the demand for combination tests increases, the number of invasive tests is drastically decreasing.
  • Reimbursement Scenario for NIPT – Health insurer Anthem Blue Cross Blue Shield has changed its medical policy regarding non-invasive prenatal testing, as such screening technology is considered medically necessary for most pregnancies, regardless of the condition. risk status. According to Anthem’s new policy, cell-free DNA-based prenatal screening for trisomy 21, 18 and 13 is medically necessary for women with a single fetus using NIPT as a screening tool for fetal aneuploidy, regardless of the risk status.

Global Non-invasive Prenatal Testing Market: Competitive Landscape

Some of the major players contributing to the global non-invasive prenatal testing market are Axia Women’s Health, Berry Genomics Corporation, Quest Diagnostics Inc., BGI Diagnosis Co., Ltd., Sequenom, Inc., Illumina, Inc., BillionToOne, Inc., LifeCodexx AG, Eluthia, Ariosa Diagnostics, Inc. and Natera, Inc .

Global Non-invasive Prenatal Testing Market: Key Developments

The major players in the global non-invasive prenatal testing market are focused on launching innovative products in order to diversify their product offering. For example, Axia Women’s Health, an independent women’s health care company located in the United States, launched non-invasive prenatal testing in the United States in August 2019.

To purchase this research report directly – https://www.coherentmarketinsights.com/insight/buy-now/579

Contents

  1. Research objectives and hypotheses
    • Research objectives
    • Hypotheses
    • Abbreviations
  2. Market Snapshot
    • Description of the report
      • Definition and scope of the market
    • Abstract
      • Market extract, by type of test
      • Market extract, by end user
      • Market extract, by region
      • Coherent Opportunity Map (COM)
  3. Analysis of market dynamics, regulations and trends
    • Market dynamics
      • Conductors
      • Constraints
      • Market opportunities
    • Impact analysis
    • Highlights
    • Product launch
    • PEST analysis
    • Technological advances
    • Regulatory scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on the market
  4. Global Non-Invasive Prenatal Testing Market, By Test Type, 2016-2027, (USD Million)
    • introduction
      • Market share analysis, 2020 and 2027 (%)
      • Year-on-year growth analysis, 2017 – 2027
      • Segment trends
    • Panel 1 test
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)
    • Panel 2 test
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)
    • Panel 3 test
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)
  5. Global Non-invasive Prenatal Testing Market, By End User, 2016-2027, (USD Million)
    • introduction
      • Market share analysis, 2020 and 2027 (%)
      • Year-on-year growth analysis, 2017 – 2027
      • Segment trends
    • Hospitals
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)
    • Diagnostic laboratories
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)
    • Maternity centers
      • introduction
      • Market Size and Forecast, and Year-on-Year Growth, 2016-2027, (USD Million)

See the press release

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, we have an office at Global Financial Capital in the US, and business consultants in UK and Japan. Our clientele includes players from various industries in more than 150 countries around the world. We pride ourselves on serving clients the full length and breadth of the horizon, from Fortune 500 companies to nonprofits and startups looking to gain a foothold in the market. We excel in delivering unmatched actionable market intelligence across a variety of industry verticals, including chemicals and materials, healthcare, food and beverage, consumer goods, packaging, semiconductors, software and services, telecommunications and automotive. We offer syndicated market intelligence reports, custom research solutions, and advisory services.

Contact:

Consistent market information
1001 4th Ave, # 3200 Seattle, WA 98154, USA
Email: [email protected]
United States of America: + 1-206-701-6702
United Kingdom: + 44-020-8133-4027
Japan: + 050-5539-1737
India: + 91-848-285-0837

Comments are closed.